30 years of historical data (1996–2025) · Healthcare · Medical - Care Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Chemed Corporation trades at 22.3x earnings, 23% below its 5-year average of 29.0x, sitting at the 52nd percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 6%. On a free-cash-flow basis, the stock trades at 17.8x P/FCF, 35% below the 5-year average of 27.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.8B | $6.2B | $8.0B | $8.9B | $7.7B | $8.4B | $8.7B | $7.3B | $4.8B | $4.1B | $2.7B |
| Enterprise Value | $5.9B | $6.2B | $8.0B | $8.8B | $7.9B | $8.7B | $8.7B | $7.5B | $4.8B | $4.2B | $2.8B |
| P/E Ratio → | 22.26 | 23.23 | 26.64 | 32.61 | 30.88 | 31.40 | 27.34 | 33.00 | 23.16 | 41.47 | 24.75 |
| P/S Ratio | 2.29 | 2.43 | 3.31 | 3.93 | 3.61 | 3.94 | 4.20 | 3.74 | 2.67 | 2.44 | 1.71 |
| P/B Ratio | 6.03 | 6.29 | 7.19 | 8.02 | 9.65 | 13.53 | 9.69 | 9.99 | 8.05 | 7.53 | 5.14 |
| P/FCF | 17.77 | 18.93 | 21.86 | 32.50 | 30.52 | 33.74 | 20.29 | 29.25 | 20.32 | 41.43 | 28.16 |
| P/OCF | 14.90 | 15.87 | 19.27 | 26.91 | 24.87 | 27.32 | 17.85 | 24.10 | 16.58 | 25.04 | 19.89 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Chemed Corporation's enterprise value stands at 17.3x EBITDA, 14% below its 5-year average of 20.0x. The Healthcare sector median is 13.8x, placing the stock at a 25% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.46 | 3.29 | 3.88 | 3.69 | 4.08 | 4.19 | 3.85 | 2.72 | 2.50 | 1.77 |
| EV / EBITDA | 17.31 | 18.42 | 18.64 | 21.87 | 19.57 | 21.69 | 19.51 | 24.69 | 17.15 | 27.97 | 13.06 |
| EV / EBIT | 17.31 | — | 19.96 | 24.84 | 23.57 | 24.77 | 21.86 | 28.07 | 19.81 | 34.32 | 15.42 |
| EV / FCF | — | 19.14 | 21.76 | 32.11 | 31.20 | 34.90 | 20.23 | 30.09 | 20.68 | 42.35 | 29.14 |
Margins and return-on-capital ratios measuring operating efficiency
Chemed Corporation earns an operating margin of 13.4%. Operating margins have compressed from 15.0% to 13.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 25.3% indicates solid capital efficiency. ROIC of 23.8% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 35.1% | 35.3% | 35.8% | 36.0% | 33.7% | 31.9% | 31.1% | 31.0% | 29.3% |
| Operating Margin | 13.4% | 13.4% | 15.1% | 15.0% | 16.1% | 16.0% | 18.7% | 13.3% | 13.7% | 6.8% | 11.3% |
| Net Profit Margin | 10.5% | 10.5% | 12.4% | 12.0% | 11.7% | 12.6% | 15.4% | 11.3% | 11.5% | 5.9% | 6.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 25.3% | 25.3% | 27.1% | 28.6% | 35.1% | 35.2% | 39.3% | 33.4% | 36.3% | 18.4% | 21.0% |
| ROA | 16.5% | 16.5% | 18.1% | 17.5% | 17.9% | 19.3% | 23.6% | 19.6% | 21.7% | 10.9% | 12.6% |
| ROIC | 23.8% | 23.8% | 26.4% | 25.9% | 27.3% | 28.8% | 32.3% | 23.9% | 28.0% | 13.6% | 22.2% |
| ROCE | 25.7% | 25.7% | 26.8% | 27.2% | 31.4% | 31.5% | 36.4% | 28.8% | 32.3% | 15.8% | 25.7% |
Solvency and debt-coverage ratios — lower is generally safer
Chemed Corporation carries a Debt/EBITDA ratio of 0.4x, which is very conservative (86% below the sector average of 3.1x). Net debt stands at $69M ($144M total debt minus $75M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.13 | 0.14 | 0.31 | 0.52 | 0.15 | 0.30 | 0.15 | 0.19 | 0.21 |
| Debt / EBITDA | 0.43 | 0.43 | 0.33 | 0.39 | 0.61 | 0.80 | 0.30 | 0.71 | 0.32 | 0.68 | 0.51 |
| Net Debt / Equity | — | 0.07 | -0.03 | -0.10 | 0.22 | 0.47 | -0.03 | 0.29 | 0.14 | 0.17 | 0.18 |
| Net Debt / EBITDA | 0.20 | 0.20 | -0.09 | -0.27 | 0.43 | 0.72 | -0.06 | 0.69 | 0.30 | 0.61 | 0.44 |
| Debt / FCF | — | 0.21 | -0.10 | -0.40 | 0.68 | 1.16 | -0.06 | 0.85 | 0.36 | 0.92 | 0.98 |
| Interest Coverage | — | — | 205.89 | 109.58 | 74.93 | 183.64 | 165.47 | 56.75 | 48.82 | 26.46 | 48.12 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.05x means Chemed Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.61x to 1.05x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | 1.05 | 1.38 | 1.61 | 0.92 | 0.76 | 1.10 | 0.73 | 0.83 | 0.91 | 0.99 |
| Quick Ratio | 1.03 | 1.03 | 1.35 | 1.57 | 0.88 | 0.73 | 1.08 | 0.70 | 0.80 | 0.88 | 0.96 |
| Cash Ratio | 0.26 | 0.26 | 0.62 | 0.85 | 0.25 | 0.11 | 0.54 | 0.02 | 0.03 | 0.06 | 0.09 |
| Asset Turnover | — | 1.64 | 1.46 | 1.36 | 1.48 | 1.59 | 1.45 | 1.53 | 1.83 | 1.81 | 1.79 |
| Inventory Turnover | — | — | 192.47 | 122.09 | 133.36 | 135.47 | 194.25 | 177.05 | 215.19 | 215.70 | 193.82 |
| Days Sales Outstanding | — | 26.34 | 25.70 | 29.26 | 23.83 | 23.41 | 22.26 | 27.08 | 24.47 | 24.89 | 30.56 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Chemed Corporation returns 8.0% to shareholders annually — split between a 0.5% dividend yield and 7.5% buyback yield. The earnings yield of 4.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.5% | 0.5% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.3% | 0.4% | 0.4% | 0.6% |
| Payout Ratio | — | — | 9.0% | 8.6% | 8.8% | 8.2% | 6.6% | 9.0% | 9.1% | 17.7% | 15.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.5% | 4.3% | 3.8% | 3.1% | 3.2% | 3.2% | 3.7% | 3.0% | 4.3% | 2.4% | 4.0% |
| FCF Yield | 5.6% | 5.3% | 4.6% | 3.1% | 3.3% | 3.0% | 4.9% | 3.4% | 4.9% | 2.4% | 3.6% |
| Buyback Yield | 7.5% | 7.0% | 4.5% | 0.8% | 1.5% | 6.8% | 2.0% | 1.3% | 3.3% | 2.3% | 3.8% |
| Total Shareholder Yield | 8.0% | 7.5% | 4.8% | 1.0% | 1.8% | 7.1% | 2.3% | 1.5% | 3.7% | 2.8% | 4.4% |
| Shares Outstanding | — | $14M | $15M | $15M | $15M | $16M | $16M | $17M | $17M | $17M | $17M |
Compare CHE with 5 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CHEYou | $6B | 22.3 | 17.3 | 17.8 | — | 13.4% | 25.3% | 23.8% | 0.4 |
| OPCH | $5B | 25.4 | 12.0 | 19.7 | 19.3% | 6.0% | 15.2% | 15.3% | — |
| ADUS | $2B | 19.9 | 13.2 | — | 32.5% | 9.7% | 9.3% | 8.8% | 1.3 |
| AVAH | $2B | -129.8 | 17.3 | 58.2 | 31.4% | 6.9% | — | 8.0% | 8.8 |
| EHAB | $686M | -4.4 | — | 14.5 | 48.7% | -11.1% | -24.9% | -7.3% | — |
| DCGO | $73M | 4.0 | 0.9 | 1.1 | 34.6% | 4.7% | 6.4% | 7.5% | 1.3 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CHE stacks up against sector leader Option Care Health, Inc..
Start ComparisonChemed Corporation's current P/E ratio is 22.3x. The historical average is 22.6x. This places it at the 52th percentile of its historical range.
Chemed Corporation's current EV/EBITDA is 17.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.4x.
Chemed Corporation's return on equity (ROE) is 25.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 18.4%.
Based on historical data, Chemed Corporation is trading at a P/E of 22.3x. This is at the 52th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Chemed Corporation's current dividend yield is 0.54%.
Chemed Corporation has 13.4% operating margin. Operating margin between 10-20% is typical for established companies.
Chemed Corporation's Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.